<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213355</url>
  </required_header>
  <id_info>
    <org_study_id>B2081009</org_study_id>
    <nct_id>NCT01213355</nct_id>
  </id_info>
  <brief_title>Scopolamine Challenge Study</brief_title>
  <official_title>A Randomized, Double-Blind, Sponsor Unblinded, Placebo Controlled, 5-Way, Crossover Study To Evaluate The Effects Of Single Oral Administrations of PF-05212377 (SAM-760), A 5-HT6 Antagonist, On Scopolamine Induced Deficits In Psychomotor And Cognitive Function In Healthy Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that PF-05212377 (SAM-760) will reverse scopolamine induced cognitive
      impairments in healthy adults subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proof of mechanism
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Groton Maze Learning Task (Total Errors); included in CogState Battery of Tests.</measure>
    <time_frame>Day 1 at 0, 5, 6, 7, 8, 10 and 12 hours of each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection Task (Speed; included in CogState Test Battery)</measure>
    <time_frame>Day 1 at 0, 5, 6, 7, 8, 10 and 12 hours of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One Card Learning Task (Accuracy of performance; included in CogState Test Battery)</measure>
    <time_frame>Day 1 at 0, 5, 6, 7, 8, 10 and 12 hours of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Paired Associate Learning Task (Number of errors; included in CogState Test Battery)</measure>
    <time_frame>Day 1 at 0, 5, 6, 7, 8, 10 and 12 hours of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bond-Lader Visual Analog Scales (included in CogState Test Battery)</measure>
    <time_frame>Day 1 at 0, 5, 6, 7, 8, 10 and 12 hours of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification Task (Speed; included in CogState Test Battery)</measure>
    <time_frame>Day 1 at 0, 5, 6, 7, 8, 10 and 12 hours of each period</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>placebo, plus scopolamine 0.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05212377 5 mg, plus scopolamine 0.5 mg;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05212377 20 mg, plus scopolamine 0.5 mg;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05212377 60 mg, plus scopolamine 0.5 mg;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>donepezil 10 mg, plus scopolamine 0.5 mg.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule, single dose, oral, 1 day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine</intervention_name>
    <description>injectable subcutaneous formulation, single dose, 1 day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212377</intervention_name>
    <description>5 mg, PF-05212377, capsule, single dose, 1 day</description>
    <arm_group_label>PF-05212377 5 mg, plus scopolamine 0.5 mg;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine</intervention_name>
    <description>injectable subcutaneous formulation, single dose, 1 day</description>
    <arm_group_label>PF-05212377 5 mg, plus scopolamine 0.5 mg;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212377</intervention_name>
    <description>20 mg, capsule PF-05212377, single dose, 1 day</description>
    <arm_group_label>PF-05212377 20 mg, plus scopolamine 0.5 mg;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>scopolamine</intervention_name>
    <description>injectable subcutaneous formulation, single dose, 1 day</description>
    <arm_group_label>PF-05212377 20 mg, plus scopolamine 0.5 mg;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212377</intervention_name>
    <description>60 mg PF-05212377, capsule, single dose, 1 day</description>
    <arm_group_label>PF-05212377 60 mg, plus scopolamine 0.5 mg;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>scopolamine</intervention_name>
    <description>injectable sub cutaneous formulation, single dose, 1 day</description>
    <arm_group_label>PF-05212377 60 mg, plus scopolamine 0.5 mg;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Tablet, 10mg, single dose, 1 day</description>
    <arm_group_label>donepezil 10 mg, plus scopolamine 0.5 mg.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine</intervention_name>
    <description>injectable sub cutaneous formulation, single dose, 1 day</description>
    <arm_group_label>donepezil 10 mg, plus scopolamine 0.5 mg.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects of non child bearing potential (WONCBP) between
             the ages of 18 and 55 years, inclusive.

          -  Body Mass index (BMI) of between 17.5 to 30.5 kg/m2 inclusive; and a total body weight
             greater than or equal to 50 kg (110 lbs).

        Exclusion Criteria:

          -  Presence or history of any disorder that may prevent the successful completion of the
             study.

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2081009&amp;StudyName=Scopolamine%20Challenge%20Study%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>September 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>October 25, 2011</last_update_submitted>
  <last_update_submitted_qc>October 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized</keyword>
  <keyword>double-blind</keyword>
  <keyword>placebo-controlled</keyword>
  <keyword>5-way crossover</keyword>
  <keyword>single oral administrations of PF 05212377</keyword>
  <keyword>scopolamine induced deficits in healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

